中国医学创新2024，Vol.21Issue(19)：49-53,5.DOI:10.3969/j.issn.1674-4985.2024.19.011
芪参益气滴丸联合重组人脑利钠肽治疗射血分数保留的心力衰竭的临床研究
Clinical Study of Qishen Yiqi Dropping Pills Combined with Recombinant Human Brain Natriuretic Peptide in the Treatment of Heart Failure with Preserved Ejection Fraction
摘要
Abstract
Objective:To investigate the clinical effect of Qishen Yiqi Dropping Pills combined with Recombinant Human Brain Natriuretic Peptide in the treatment of heart failure with preserved ejection fraction(HFpEF).Method:A total of 69 HFpEF patients admitted to Jiujiang NO.1 People's Hospital from January to October 2023 were selected.They were divided into group A,group B and group C by random number method,with 23 cases in each group.Group A was treated with anti-heart failure routine treatment,group B was treated with Qishen Yiqi Dropping Pills on the basis of group A,and group C was treated with Recombinant Human Brain Natriuretic Peptide for Injection on the basis of group B.The results of left atrial diameter(LA),left ventricular ejection fraction(LVEF),left ventricular fraction shortening(LVFS),ratio of early diastolic peak mitral valve flow rate to end-diastolic peak mitral valve flow rate(E/A),serum N-terminal pro-brain natriuretic peptide(NT-proBNP)and 6-min walking test(6MWT)were compared between the three groups before and after treatment.The incidence of adverse reactions and re-hospitalization were recorded in the three groups.Result:There were no significant differences in LA between the three groups before treatment and 6 weeks after treatment(P>0.05).After 6 weeks of treatment,NT-proBNP in the three groups was lower than that before treatment,LVEF,LVFS,E/A,6MWT in the three groups were higher than those before treatment,meanwhile,NT-proBNP in group C was lower than that in group A and group B,LVEF,LVFS,E/A,6MWT in group C were higher than those in group A and group B,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).There was statistical significance in the re-hospitalization rate among the three groups(P<0.05);the re-hospitalization rate of group C was lower than that of group A and group B,the differences were statistically significant(P<0.05).Conclusion:Qishen Yiqi Dripping Pills combined with Recombinant Human Brain Natriuretic Peptide in the treatment of HFpEF patients can effectively improve the cardiac function,improve the walking ability of patients,reduce the re-hospitalization rate,with satisfactory treatment effect and high safety.关键词
芪参益气滴丸/重组人脑利钠肽/心力衰竭/心功能Key words
Qishen Yiqi Dripping Pills/Recombinant Human Brain Natriuretic Peptide/Heart failure/Cardiac function引用本文复制引用
郭磊,雷梅先,余彬,高灵..芪参益气滴丸联合重组人脑利钠肽治疗射血分数保留的心力衰竭的临床研究[J].中国医学创新,2024,21(19):49-53,5.基金项目
江西省中医院管理局科技计划项目(2022B812) （2022B812）
